Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1802 in Moderate to Severe Atopic Dermatitis (Phase Ib/II)
CTR20212483Phase 2Completed
- Sponsor
- Zhixiang (Shanghai) Pharmaceutical Technology Co., Ltd.
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of telikibart in atopic dermatitis (AD), sponsored by Zhixiang (Shanghai) Pharmaceutical Technology Co., Ltd.. Started Oct 2021; status: completed.
02
Drugs
telikibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20212483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212483.